Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Cancer Res ; 29(13): 2375-2384, 2023 07 05.
Article in English | MEDLINE | ID: mdl-37036505

ABSTRACT

PURPOSE: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferation and induce apoptosis of JAK2V617F-mutant cell lines. PATIENTS AND METHODS: In a phase I dose-escalation and -expansion study, we evaluated the safety and efficacy of a selective PI3Kδ inhibitor, umbralisib, in combination with ruxolitinib in patients with MF who had a suboptimal response or lost response to ruxolitinib. Enrolled subjects were required to be on a stable dose of ruxolitinib for ≥8 weeks and continue that MTD at study enrollment. The recommended dose of umbralisib in combination with ruxolitinib was determined using a modified 3+3 dose-escalation design. Safety, pharmacokinetics, and efficacy outcomes were evaluated, and spleen size was measured with a novel automated digital atlas. RESULTS: Thirty-seven patients with MF (median age, 67 years) with prior exposure to ruxolitinib were enrolled. A total of 2 patients treated with 800 mg umbralisib experienced reversible grade 3 asymptomatic pancreatic enzyme elevation, but no dose-limiting toxicities were seen at lower umbralisib doses. Two patients (5%) achieved a durable complete response, and 12 patients (32%) met the International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria of clinical improvement. With a median follow-up of 50.3 months for censored patients, overall survival was greater than 70% after 3 years of follow-up. CONCLUSIONS: Adding umbralisib to ruxolitinib in patients was well tolerated and may resensitize patients with MF to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors. Randomized trials testing umbralisib in the treatment of MF should be pursued.


Subject(s)
Janus Kinase Inhibitors , Primary Myelofibrosis , Humans , Aged , Primary Myelofibrosis/drug therapy , Primary Myelofibrosis/metabolism , Phosphatidylinositol 3-Kinases , Pyrimidines/therapeutic use , Nitriles/therapeutic use , Janus Kinase Inhibitors/therapeutic use
2.
Semin Oncol Nurs ; 35(5): 150931, 2019 10.
Article in English | MEDLINE | ID: mdl-31477411

ABSTRACT

OBJECTIVE: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS). DATA SOURCES: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events. CONCLUSION: Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research. Prompt recognition and management of the side effects of CAR T-cell therapy is pivotal to the safe outcomes of patients. As patients are treated with these novel therapies, additional recommendations and standards for treating CRS and neurotoxicity will occur. IMPLICATION FOR NURSING PRACTICE: Nursing plays a pivotal role in the CAR T patients' treatment course because they are the first line of defense in the care of these patients. Providers and patients both rely on nursing knowledge and training to recognize symptoms of CRS and neurotoxicity. With the early recognition of the signs and symptoms of CRS and neurotoxicity, nursing will help improve the outcomes of the patients receiving CAR T-cell therapy.


Subject(s)
Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/therapy , Immunotherapy, Adoptive/adverse effects , Neoplasms/therapy , Oncology Nursing/methods , Receptors, Antigen, T-Cell/drug effects , Receptors, Chimeric Antigen/therapeutic use , Humans , Neoplasms/immunology
3.
Semin Oncol Nurs ; 35(5): 150930, 2019 10.
Article in English | MEDLINE | ID: mdl-31561845

ABSTRACT

OBJECTIVE: To discuss the mechanism of action and nursing care of adults receiving chimeric antigen receptor (CAR) T-cell therapy. DATA SOURCE: Peer reviewed articles and pharmaceutical drug labels. CONCLUSION: CAR T-cell therapy is among the most exciting therapies in the evolution of cancer treatment. The efficacy of research with CAR T-cell therapy has shown promising results in hematologic malignancies as well as in solid tumors. IMPLICATIONS FOR NURSING PRACTICE: Understanding the complexity of care for these patients from the bedside to the outpatient setting is vital for their survival and quality of care.


Subject(s)
Immunotherapy, Adoptive/methods , Immunotherapy/methods , Neoplasms/immunology , Neoplasms/therapy , Oncology Nursing/methods , Receptors, Antigen, T-Cell/drug effects , Receptors, Chimeric Antigen/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
4.
Biol Blood Marrow Transplant ; 22(3): 528-35, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26705931

ABSTRACT

Hematopoietic stem cell transplantation (HCT) survivors are less likely than matched healthy controls to mount a strong immune response to trivalent inactivated influenza vaccine (TIV). High-dose (HD) or standard-dose (SD) TIV were given to adult HCT subjects 18 years or older at least 6 months after transplantation. Subjects were randomized 2:1 to receive either the HD (60 µg hemagglutinin [HA]/strain/dose) or the SD (15 µg HA/strain/dose) TIV. Injection-site and systemic reactions were documented after each vaccination and immune responses were measured before and after each vaccination. A total of 44 subjects were enrolled (25 in year 1 and 19 in year 2), with 15 in the SD group and 29 in the HD group. The median time to vaccination after transplantation was 7.9 months (range, 6 to 106 months), the median age was 50 years (range, 19.6 to 73 years), and 61% were male. No differences in demographic or lab data were noted between groups; however, the HD group had higher median baseline total IgG level (676 versus 469 mg/dL, P = .025). No differences in individual injection-site or systemic reactions were noted between groups; however, more events of any injection-site symptom combined were reported in the HD group. No serious adverse events were attributed to vaccination. After vaccination, the HD group had a higher percentage of individuals with titers ≥1:40 and a higher geometric mean titer (GMT) against the H3N2 strain compared with that of the SD group. HD and SD TIV were found to be safe and well tolerated in adult HCT recipients. However, the HD group had higher frequency of injection-site reactions but the majority of the reactions were mild and resolved. The HD group had a higher percentage of individuals with post-vaccination titer ≥ 1:40 and GMT for H3N2 antigen, indicating better immunogenicity. These data support the need for a phase II immunogenicity trial in HCT recipients.


Subject(s)
Antibodies, Viral/blood , Antibody Specificity , Hematopoietic Stem Cell Transplantation , Immunoglobulin G/blood , Influenza A Virus, H3N2 Subtype , Influenza Vaccines/administration & dosage , Adult , Allografts , Antibodies, Viral/immunology , Double-Blind Method , Female , Follow-Up Studies , Humans , Immunoglobulin G/immunology , Influenza Vaccines/adverse effects , Influenza Vaccines/immunology , Male , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...